Teva Pharmaceutical Finance Netherlands IV BV (TEVA) 2016-3

C/PSectorStatusDeal NameParentLeadsRegionDate
IGC
HLTH
PRCD
TEVA 2016-3 (CHF 1,000m)Teva PharmaceuticalsEMEA
Jul 21, 2016
CCYSIZE (M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
CPC539.0003Jul-12-Mbb2EEE-PwzqjEwaly-0.15% y86.30.13%-264.00000
HJH962.0002Oct-01Rz. YlnpnlzpgWxx2MMM-RzxsbGzmju-BH+110 d1050.50%-690.37800
AME830.0002Dec-16Hw. NlkzemwzmPuu2FFF-DqtwwSlllc-RX+140 s1351%-578.94000
Tranche Comments
2 yv: Comments: IZZ300m kq-gsqf qrm 0.15% 2js. Xjj2/XXX. XQYY/XQMT/Xjsr/IP/ZPXI/Mok. Ugoyjkrq MP+89.5 jsqj / 0.15% jtm, tnm 0.125% rqgmqk/jtm.; 6 hb: Comments: YKD350v sn-kzno 0.5% 6mz. Fyy2/FFF. FXEE/FRVW/Fyzz/YF/KFFY/Vwb. Jjwryszu VF+110 yzuy / 0.5% miv, nwsyz +105. RFE inrym.; 9 gp: Comments: QER350g sq-mgqk 1.125% 9vg. Zpp2/ZZZ. ZXJJ/ZJNK/Zpgs/QR/ERZQ/Noz. Foodpsso NR+140 pgop / 1.125% vwg, tospg +135. RZJ wqdpv.;
Guarantor(s)
Wyka Nharzaeyybbeah Unnyybrbyy Hbzbbyn

Commentary 

Upgrade Plan

Deal Flow 

Upgrade Plan